Ozempic may offer a surprising bonus benefit for brain health
A new analysis suggests that people with type 2 diabetes who use GLP-1 medications like Ozempic, Trulicity or Victoza may be less likely to develop epilepsy than those taking DPP-4 inhibitors. Semaglutide showed the strongest connection to lowered risk. Researchers caution that the findings show an association, not proof of cause and effect. More rigorous […]
One GLP-1 Drug May Be Better Than Rivals for Glaucoma Risk
(MedPage Today) — Use of the dual GIP/GLP-1 drug tirzepatide (Mounjaro, Zepbound) was associated with a significantly reduced risk of glaucoma compared with GLP-1 drugs among patients with type 2 diabetes, a large retrospective cohort study suggested…
Biomedicines, Vol. 13, Pages 3079: Added Value to GLP-1 Receptor Agonist: Intermittent Fasting and Lifestyle Modification to Improve Therapeutic Effects and Outcomes
Biomedicines, Vol. 13, Pages 3079: Added Value to GLP-1 Receptor Agonist: Intermittent Fasting and Lifestyle Modification to Improve Therapeutic Effects and Outcomes Biomedicines doi: 10.3390/biomedicines13123079 Authors: Dragos Cozma Cristina Văcărescu Claudiu Stoicescu Obesity remains a major global health challenge, with glucagon-like peptide-1 receptor agonists (GLP-1RAs) providing substantial yet sensitive benefits in weight reduction, glycemic control, […]
Effectiveness of Pre‐Transplant Dual GLP‐1 Receptor Agonist and SGLT2 Inhibitor Therapy on All‐Cause Mortality in Organ Transplantation Candidates with Obesity and Type 2 Diabetes: a Target‐Trial Emulation
This target trial emulation in solid organ transplant candidates with obesity and type 2 diabetes evaluates whether pre-transplant dual therapy with GLP-1 receptor agonists plus SGLT2 inhibitors is associated with post-transplant mortality and kidney graft outcomes compared with monotherapy or usual care, using multinational electronic health records and extensive sensitivity analyses. Abstract Evidence on pre-transplant […]
New Weight-Loss Pills Could Arrive Sooner Than We Think
Yevgen_Rychko / Getty Images Millions of Americans have successfully lost weight with semaglutides, the game-changing class of drugs that includes Ozempic, Mounjaro, and Wegovy. Still, many others are holding out for GLP-1 medication to arrive in pill form—and they may not have to wait much longer. Orforglipron, a GLP-1 agonist administered as a pill, is […]
Ozempic explained: How this hormone-based drug actually works
Introducing Ozempic, a groundbreaking GLP-1 agonist now making waves in India! This innovative treatment emulates a natural gut hormone, providing a new approach for managing type 2 diabetes and obesity. By enhancing insulin production and lowering glucagon levels, it assists in stabilizing blood sugar. Plus, it helps you feel satisfied longer by slowing down digestion […]
Eli Lilly’s Next-Generation Obesity Drug Secures First Phase III Win
Shares of Eli Lilly LLY rose nearly 2% on Thursday after the company announced that a late-stage study evaluating its experimental once-weekly weight-loss drug, retatrutide, met all primary and key secondary endpoints. This study, called TRIUMPH-4, evaluated two doses (9 mg and 12 mg) of the drug for 68 weeks against placebo in adults with obesity […]
Doctors call for cigarette-style warning label on GLP-1 drugs like Ozempic due to this ‘very dangerous’ risk
“Both restriction and purging behaviors are reinforced by GLP-1s.”
Can Non-Diabetics Take Ozempic For Weight Loss? Doctor Answers
Ozempic is the brand name for a medication called semaglutide, which is primarily used to manage type 2 diabetes. It belongs to a class of drugs known as GLP-1 receptor agonists
Semaglutide Lowers SGA-Related Cardiometabolic Risk
Adjunctive treatment with the GLP-1 agonist semaglutide significantly reduces the antipsychotic-related cardiometabolic risk in individuals with schizophrenia spectrum disorders compared with placebo. Medscape Medical News